Related Experiment Video
Updated: Jul 19, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized
Kenneth B Gordon1, Richard G Langley, Craig Leonardi
1Division of Dermatology, Evanston Northwestern Healthcare and Northwestern University Feinberg School of Medicine, Skokie, IL 60077, USA. kgordon@enh.org
Background:
Tumor necrosis factor is pivotal in the pathogenesis of psoriasis. Adalimumab is a fully human monoclonal immunoglobulin G1 antibody that neutralizes tumor necrosis factor.
Objectives:
We sought to assess the efficacy and safety of adalimumab in patients with moderate to severe plaque psoriasis.
Methods:
In this multicenter, randomized, double-blind, placebo-controlled study, 147 patients received adalimumab (40 mg every other week or 40 mg/wk) or placebo. After 12 weeks of blinded therapy, patients taking adalimumab could continue their assigned dosages in a 48-week extension trial; patients taking placebo were switched to adalimumab (40 mg every other week).
Results:
At week 12, 53% of patients taking adalimumab every other week, 80% of patients taking adalimumab weekly, and 4% of patients taking placebo achieved 75% improvement in Psoriasis Area and Severity Index score (P < .001). Responses were sustained for 60 weeks. No new safety signals were noted compared with the existing adalimumab clinical safety database.
Limitations:
The study was insufficiently powered to detect rare adverse events associated with adalimumab.
Conclusions:
Adalimumab significantly improved psoriasis and was well tolerated for 60 weeks.